Q2 2025 Verrica Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Verrica Pharmaceuticals Inc (VRCA) reported a record 13,434 YCANTH dispensed applicator units in the second quarter, representing a 32.8% sequential quarterly growth.
- The company secured an $8 million milestone payment from Torii Pharmaceutical, strengthening their financial position.
- Verrica Pharmaceuticals Inc (VRCA) achieved a gross product margin of approximately 93% for the second quarter of 2025.
- The company has successfully implemented a focused commercial strategy, resulting in decreased selling, general, and administrative expenses by $7.7 million compared to the previous year.
- Verrica Pharmaceuticals Inc (VRCA) reported a GAAP net income of $0.2 million for the second quarter of 2025, compared to a net loss in the same period last year.
- Net YCANTH revenue decreased to $4.5 million in the second quarter of 2025 from $4.9 million in the same period of 2024.
- The company faces inherent risks and uncertainties in its forward-looking statements, which could impact actual results.
- Verrica Pharmaceuticals Inc (VRCA) has cash and cash equivalents of $15.4 million, which may not be sufficient to fund operations for the next year without additional financing.
- The company is reliant on milestone payments and potential warrant exercises to bolster its financial position.
- There is a potential for lumpiness in revenue due to the specialty distributor's stocking orders, which could affect quarterly financial results.
Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals second-quarter 2025 corporate update conference call. (Operator Instructions) As a reminder, this conference is being recorded.
I will now turn the call over to your host, Kevin Gardner of LifeSci Advisors. You may begin your conference.
Thank you, operator. Hello, everyone, and welcome to Verrica Pharmaceuticals second-quarter 2025 corporate update conference call. With me on the line this evening are Jayson Rieger, President and Chief Executive Officer of Verrica Pharmaceuticals; Noah Rosenberg, Chief Medical Officer; John Kirby, Interim Chief Financial Officer; and David Zawitz, Chief Operating Officer.
As a reminder, during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verrica's actual results and the timing of events could differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
